共 50 条
Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients
被引:43
|作者:
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构:
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词:
lamivudine-resistant HBV strains;
hepatitis B virus;
human immunodeficiency virus;
HBV-HIV coinfection;
sub-Saharan Africa;
D O I:
10.1002/jmv.20974
中图分类号:
Q93 [微生物学];
学科分类号:
071005 ;
100705 ;
摘要:
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文